Cannabidiol for Epilepsy: New Hope on the Horizon?

Paul E. Sanmartin, Kamil Detyniecki

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Epilepsy is a common neurologic disorder; it is estimated that ∼50 million people are affected worldwide. About one third of those patients are drug resistant, defined as failure to stop all seizures despite adequate trials of at least 2 appropriate medications. There has been an enormous interest in developing antiepileptic drugs with novel mechanisms of action. This review discusses the evidence supporting the anticonvulsant properties of cannabis in humans, focusing on cannabidiol. We begin by exploring the early and somewhat anecdotal evidence that was recently replaced by high-quality data from randomized controlled studies, which subsequently led to the US Food and Drug Administration approval of a purified cannabidiol extract for the treatment of 2 highly refractory pediatric epilepsy syndromes (Dravet and Lennox-Gastaut).

Original languageEnglish (US)
Pages (from-to)1438-1441
Number of pages4
JournalClinical Therapeutics
Issue number9
StatePublished - Sep 2018
Externally publishedYes


  • cannabidiol
  • cannabis
  • epilepsy
  • marijuana
  • seizures

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cannabidiol for Epilepsy: New Hope on the Horizon?'. Together they form a unique fingerprint.

Cite this